IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

▤ Summary

IMU Biosciences has selected Waters to help scale its AI-powered HD Immunology platform. The partnership combines Waters’ flow cytometry and single-cell technologies with IMU’s machine learning analytics to generate deeper immune insights from blood samples. The companies want to expand population-level immune mapping and support translational and clinical research in cancer and other diseases. They also plan additional studies for biomarker discovery and future clinical applications. This deal strengthens IMU’s platform development and expands the use of advanced analytical tools in life sciences research.

▦ Linked Companies